Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Phase 1/2 Recruiting 434 enrolled Vivace Therapeutics, Inc

Non-randomizedSequentialOpen-labelTreatment

Summary

This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which no effective standard therapy is available.

Timeline

Start: 2021-03-24
Primary completion: 2029-11-02
Completion: 2030-03-02

Publications

Yap TA, Kwiatkowski DJ, Dagogo-Jack I, Offin M, Zauderer MG, Kratzke R, Desai J, Body A, Millward M, Tolcher AW, Raghav KPS, Thurston A, Post L, Dorr FA, Tang TT, Li Y, Sharma N, Kindler HL. YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial. Nat Med. 2025 Dec;31(12):4281-4290. doi: 10.1038/s41591-025-04029-3. Epub 2025 Oct 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VT3989	Unknown	25 mg	Oral
Subject	VT3989	Unknown	50 mg	Oral
Subject	VT3989	Unknown	100 mg	Oral
Subject	VT3989	Unknown	150 mg	Oral
Subject	VT3989	Unknown	200 mg	Oral
Background	Carboplatin	Small molecule	5 unknown	Intravenous
Background	Ipilimumab	Monoclonal antibody	1 mg/kg	Intravenous
Background	Nivolumab	Monoclonal antibody	360 mg	Intravenous
Background	Osimertinib	Small molecule	40 mg	Oral
Background	Osimertinib	Small molecule	80 mg	Oral
Background	Pemetrexed	Small molecule	500 mg/m2	Intravenous

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Summary

Timeline

Publications

Drugs

Indications